Autor según el artículo: Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez-Tembra M, Civeira F, Dyslipemia Registry of Spanish Arteriosclerosis Society
Departamento: Medicina i Cirurgia
Autor/es de la URV: Plana Gil, Núria
Palabras clave: Statins Risk Mutation Mortality Management Lipid-lowering Guidelines Guidance Familial hypercholesterolemia Diagnosis Coronary-heart-disease Cholesterol Cardiovascular disease Association lipid-lowering familial hypercholesterolemia cardiovascular disease
Resumen: The impact on heterozygous familial hypercholesterolemia (HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and the question remains if there is still an unacceptably high residual risk to justify treatment with new lipid-lowering drugs.This observational, retrospective, multicenter, national study in Spain, whose information was obtained from a national dyslipemia registry, was designed to establish the current prevalence of cardiovascular disease (CVD) in HeFH and to define the impact of HILLT on CVD in this population. Odds were estimated using several logistic regression models with progressive adjustment.1958 HeFH, mean age 49.3?±?14.3 years, were included in the analysis. At inclusion in the registry, 295 patients (15.1%) had suffered CVD and 164 (55.6%) had suffered the first event before the onset lipid-lowering treatment. Exposition to treatment associated more than ten times lower odds for CVD than in subjects naïve to treatment (OR 0.085, 95% CI 0.063-0.114, p?<?0.001). A first CVD event after a mean treatment period of 9.1?±?7.2 years occurred in 131 out of 1615 (8.1%) HeFH subjects, and 115 (87.8%) of them were on HILLT.Current prevalence of CVD among HeFH is one third of that reported before the statins era. Early initiation and prolonged lipid-lowering treatment was associated with a reduction in CVD. New cases of CVD, in spite of HILLT, appeared mostly among patients accumulating risk factors and probably they may be considered for further lipid-lowering drugs.Copyright © 2019 Elsevier B.V. All rights reserved.
Áreas temáticas: Saúde coletiva Psicología Peripheral vascular disease Odontología Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Ciência da computação Cardiology and cardiovascular medicine Cardiac & cardiovascular systems Biotecnología Antropologia / arqueologia
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00219150
Direcció de correo del autor: nuria.plana@urv.cat
Identificador del autor: 0000-0002-4231-7618
Fecha de alta del registro: 2023-02-18
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
Enlace a la fuente original: https://www.atherosclerosis-journal.com/article/S0021-9150(19)30081-4/fulltext
Referencia al articulo segun fuente origial: Atherosclerosis. 284 245-252
Referencia de l'ítem segons les normes APA: Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez (2019). Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis, 284(), 245-252. DOI: 10.1016/j.atherosclerosis.2019.02.003
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI del artículo: 10.1016/j.atherosclerosis.2019.02.003
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2019
Tipo de publicación: Journal Publications
Repositori URV